Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 1 5 versus FLOVENT DISKUS 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 1 5 versus FLOVENT DISKUS 100.
DEXONE 1.5 vs FLOVENT DISKUS 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a long-acting glucocorticoid receptor agonist that suppresses inflammation and immune responses by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating gene expression.
Fluticasone propionate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and suppresses eosinophil activity.
1.5 mg orally once daily
100 mcg inhaled orally twice daily
None Documented
None Documented
Terminal half-life approximately 3-4 hours (dexamethasone), with clinical effects persisting 36-54 hours due to glucocorticoid receptor-mediated actions.
The terminal elimination half-life of fluticasone propionate is approximately 7.8 hours (range 5-11 hours) following inhalation. This supports twice-daily dosing, though the therapeutic effect is driven by local lung retention rather than systemic half-life.
Renal (primarily as metabolites, ~60%), biliary/fecal (~30%), with <5% excreted unchanged.
Fluticasone propionate is primarily eliminated via hepatic metabolism (CYP3A4) with less than 5% of a dose excreted unchanged in urine. Fecal excretion accounts for approximately 90% of the absorbed dose (as metabolites). Biliary elimination is minimal.
Category C
Category C
Corticosteroid
Corticosteroid